The multi-omics approaches have been approved as effective tools for deciphering the complex, multi-dimensional biological interactions in CLL, such as understanding the proliferative drive of CLL cells [80], exploring mechanisms associated with CLL relapses during anti-BCL2 targeted therapy [81], as well as developing novel targeted therapies for CLL [82]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.